saruplase

09/01/1999 - "Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. "
02/15/1996 - "Sequential electrocardiograms for admission to 36 hours in 358 patient s with acute myocardial infarction (AMI) from the Pro-urokinase In Myocardial Infarction trial were assessed. "
01/01/1995 - "Dose finding studies in patients with acute myocardial infarction indicated that a dose of 80 mg of saruplase, given as a bolus of 20 mg and iv infusion of 60 mg in one hour, led to excellent patency figures.Saruplase"
12/15/1991 - "The Pro-Urokinase for Myocardial Infarction Study Group."
03/01/1999 - "Pharmacology and clinical trial results of saruplase (scuPA) in acute myocardial infarction."

02/01/1999 - "Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model."
05/01/1997 - "Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model."
03/01/1997 - "The fibrinolytic properties of M23 and saruplase were compared in anaesthetized dogs with femoral artery and saphenous vein thrombosis. "
12/15/1991 - "In a rabbit femoral artery thrombosis model infusion of saruplase (3 - 12 mg/kg, 60 min) caused a dose-dependent thrombolysis. "
10/01/1990 - "Infusion of saruplase (21.5 micrograms/kg.min) for 60 min significantly increased the 125J-fibrinolysis to 36.8 +/- 3.7% and the reduction of the thrombus weight to 69.9 +/- 2.1%. "

03/01/1997 - "The maximal dissolution of 125I-fibrin in the venous thrombosis model was 91 +/- 1% in M23- and 88 +/- 5% in saruplase-treated animals. "
09/01/1994 - "A pilot study of pro-urokinase in the treatment of deep vein thrombosis."
08/01/2018 - "Administration routes affect thrombolytic effect of catheter-directed thrombolysis with pro-urokinase in treating deep vein thrombosis."
09/01/1994 - "Safety and efficacy of the thrombolytic agent pro-urokinase (pro-UK) in the treatment of deep vein thrombosis of the lower limbs (DVT) have been investigated in an open, uncontrolled, pilot study. "
03/01/1997 - "A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs."

01/01/2002 - "The role of recombinant pro-urokinase (r-pro-UK) and intra-arterial thrombolysis in acute ischaemic stroke: the PROACT trials. "
08/01/2003 - "Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS."
06/01/1998 - "Intra-arterial pro-urokinase in ischemic stroke."
11/13/2001 - "To analyze the frequency, clinical characteristics, and predictors of symptomatic intracerebral hemorrhage (ICH) after intraarterial (IA) thrombolysis with recombinant pro-urokinase (r-proUK) in acute ischemic stroke. "
08/09/2022 - "Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial."

01/01/1998 - "PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. "
05/01/2003 - "The PROACT II study demonstrated a significant benefit from treatment with intra-arterial pro-urokinase (r-proUK) in patients with middle cerebral artery occlusion treated within 6 hours of stroke onset. "
01/01/1998 - "To test the safety and recanalization efficacy of intra-arterial local delivery of plasminogen activators in acute ischemic stroke, a randomized trial of recombinant pro-urokinase (rpro-UK) versus placebo was undertaken in patients with angiographically documented proximal middle cerebral artery occlusion. "